Shedding of the Her2 ECD by metalloproteases or alternative translational initiation can produce CTFs no longer recognizable by the monoclonal antibody cancer drug Herceptin (reviewed in [39]), presenting challenges to treating Her2-positive breast cancers and also mechanisms for Herceptin resistance. This evidence concerns the gene ERBB2 and breast carcinoma.